ArticleScientific reports2025
Neuroprotective effects of Pycnogenol on nerve regeneration and functional recovery after sciatic nerve crush injury in rodents.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potential of pycnogenol: antioxidant, anti-inflammatory, immunomodulatory, antiviral, and anticancer effects.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pycnogenol, a standardized French maritime pine bark extract, is known for its antioxidant, anti-inflammatory, and neuroprotective properties. This study evaluated its therapeutic potential in sciatic nerve regeneration following crush injury in female Sprague Dawley rats. Twenty-one rats were assigned to Sham, Control, and Pycnogenol (100 mg/kg/day) groups. After standardized nerve injury, Pycnogenol was administered for 28 days. Functional recovery was assessed using the Sciatic Functional Index (SFI), pinprick, and cold allodynia tests. Histopathology, muscle weight, and ELISA for nerve growth factor (NGF) were evaluated post-euthanasia. By Day 14, the Pycnogenol group showed significantly better SFI scores (83.60 ± 2.26 vs. 89.81 ± 2.42, p < 0.001), with continued improvement through Day 28 (49.42 ± 3.0 vs. 62.95 ± 2.93, p < 0.001). Histological analysis revealed enhanced muscle regeneration, increased fiber area, and improved myelination. ELISA confirmed significantly elevated NGF levels, supporting Pycnogenol's neuroprotective role. These findings highlight its potential in peripheral nerve injury treatment. Further research is needed to confirm efficacy in humans, explore molecular mechanisms, and compare it with existing neuro-regenerative therapies. Pycnogenol may serve as a promising agent in neurology and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.